[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491834":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":38,"centralContacts":11,"locations":41,"responsibleParty":65,"collaborators":11,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":11,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":11,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":89,"whyStopped":11,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,15,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: BMS-986278 + Sildenafil","EXPERIMENTAL",null,[13,14],"Drug: BMS-986278","Drug: Sildenafil",{"label":16,"type":17,"description":11,"interventionNames":18},"Part 1: Placebo + Sildenafil","PLACEBO_COMPARATOR",[14,19],"Drug: Placebo",{"label":21,"type":10,"description":11,"interventionNames":22},"Part 2: BMS-986278",[13],{"label":24,"type":17,"description":11,"interventionNames":25},"Part 2: Placebo",[19],[27,32,35],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","BMS-986278","Specified dose on specified days",[9,21],{"type":28,"name":33,"description":30,"armGroupLabels":34,"otherNames":11},"Sildenafil",[9,16],{"type":28,"name":36,"description":30,"armGroupLabels":37,"otherNames":11},"Placebo",[16,24],[39],{"name":5,"affiliation":5,"role":40},"STUDY_DIRECTOR",[42,55],{"facility":43,"status":11,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":11},"Altasciences Clinical Los Angeles, Inc","Cypress","California","90630","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-118.03729,33.81696,{"lat":53,"lon":52},{"facility":56,"status":11,"city":57,"state":58,"zip":59,"country":47,"countryCode":48,"cosmosGeoPoint":60,"geoPoint":64,"contacts":11},"Syneos Health Clinical Research Services, Llc","Miami","Florida","33136",{"type":50,"coordinates":61},[62,63],-80.19366,25.77427,{"lat":63,"lon":62},{"type":66,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100491834","phase-1-a-study-investigating-the-safety-tolerability-drug-levels-and-drug-effect-of-bms-986278-in-healthy-adult-participants-part-1-and-japanese-participants-part-2-100491834",false,"NCT05684289","A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)","A Phase 1, 2-Part, Randomized, Double-Blind, Placebo-controlled, Multiple Dose Study to Test the Potential Interaction of a PDE5 Inhibitor With BMS-986278 and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986278 in Healthy Adult Participants (Part 1) and in Japanese Participants (Part 2)","Inclusion Criteria:\n\n* Participants in the Japanese cohort (Part 2) must be first generation Japanese (born in Japan, not living outside of Japan \\> 10 years, both parents ethnically Japanese).\n* Body mass index (BMI) of 18.0 kilogram (kg)\u002Fmeter (m)\\^2 through 32.0 kg\u002Fm\\^2, inclusive. BMI = weight (kg)\u002F(height \\[m\\])\\^2.\n* Body weight ≥ 50 kg for males and ≥ 45 kg for females.\n\nExclusion Criteria:\n\n* Any significant acute or chronic medical illness.\n* Any gastrointestinal (GI) disease or surgery (including cholecystectomy) or other procedures (for example, bariatric procedures) that could affect drug absorption, distribution, metabolism, and excretion.\n* Any major surgery within 4 weeks of first study intervention administration.\n\nOther protocol-defined inclusion\u002Fexclusion criteria apply.",true,"ALL","35 Years","65 Years",{"count":79,"type":80},61,"ACTUAL","INTERVENTIONAL",[83],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.",[86],"Healthy Participants",[29,88,33],"Idiopathic Pulmonary Fibrosis (IPF)","COMPLETED","2023-08-23",{"date":92,"type":80},"2023-08-24",{"date":94,"type":80},"2023-01-03",{"date":96,"type":80},"2023-05-02",{"name":5,"class":6},2]